Haleos Labs Limited
NSE: HALEOSLABS · Pharmaceuticals
Snapshot
Unlock Haleos Labs Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Haleos Labs Limited is an Indian pharmaceutical company specialising in the manufacturing of active pharmaceutical ingredients (API) and intermediates. The company serves a diverse range of therapeutic segments, including anti-ulcer, anti-cancer, and anti-hypertensive treatments, and maintains an international export presence.
Business Model
The company generates revenue through the large-scale production and sale of pharmaceutical intermediates and APIs to domestic and international markets. It leverages its manufacturing capabilities to supply a broad portfolio of therapeutic products to the global healthcare industry.
- Founded:1990
Management Commentary
Management recently oversaw a corporate rebranding, transitioning from SMS Lifesciences India Limited to Haleos Labs Limited in August 2025 to reflect its evolving market identity.
Growth Outlook
Growth is driven by the company's extensive portfolio of specialised API products and its established export operations. Continued focus on diverse therapeutic areas positions the firm to capture demand in both domestic and global pharmaceutical markets.
Key Risks
- Regulatory Compliance. The company faces stringent oversight from global health authorities, where any failure to meet manufacturing standards could lead to product recalls or export bans.
- Raw Material Price Volatility. Fluctuations in the cost of key starting materials and chemical intermediates can significantly impact operating margins.
- Foreign Exchange Risk. As an exporter, the company is exposed to currency volatility which may affect the competitiveness and profitability of its international sales.
- Competitive Pressure. The API manufacturing sector is highly fragmented, leading to intense price competition from other low-cost generic manufacturers.
Start your research today
Unlock AI insights, financials, peers and live data on Haleos Labs Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹324 Cr
TTM · consolidated
NET PROFIT
₹15 Cr
TTM · consolidated
EPS
₹52.27
TTM · consolidated
RETURN ON EQUITY
7.4%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
10.3%
TTM · consolidated
P/E
28.5×
Q1 FY27 · consolidated
EV/EBITDA
12.8x
Q1 FY27 · consolidated
EBITDA MARGIN
13.6%
TTM · consolidated
NET PROFIT MARGIN
2.5%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.5x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Haleos Labs LimitedHALEOSLABS | ₹457 Cr | 28.5× | 12.83 | -3.1% | 13.6% | 7.4% | 10.3% | — |
Influx Health.INFLUX | ₹655 Cr | — | — | — | 20.0% | — | — | +51.5% |
TranschemTRANSCHEM | ₹502 Cr | 75.6× | 52.99 | -100.0% | 177.7% | 8.3% | 10.6% | +600.8% |
Albert DavidALBERTDAVD | ₹501 Cr | 21.7× | 13.19 | 11.4% | 11.0% | 5.8% | 7.5% | +10.3% |
Medicamen BiotecMEDICAMEQ | ₹434 Cr | 43.0× | 19.76 | 24.7% | 11.3% | 4.1% | 6.2% | +5.9% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹420 Cr | 12.3× | 8.20 | — | 30.0% | 16.7% | 21.5% | -15.2% |
As of Q1 FY27
Financials
Haleos Labs Limited
NSE: HALEOSLABS · Pharmaceuticals
Snapshot
Unlock Haleos Labs Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Haleos Labs Limited is an Indian pharmaceutical company specialising in the manufacturing of active pharmaceutical ingredients (API) and intermediates. The company serves a diverse range of therapeutic segments, including anti-ulcer, anti-cancer, and anti-hypertensive treatments, and maintains an international export presence.
Business Model
The company generates revenue through the large-scale production and sale of pharmaceutical intermediates and APIs to domestic and international markets. It leverages its manufacturing capabilities to supply a broad portfolio of therapeutic products to the global healthcare industry.
- Founded:1990
Management Commentary
Management recently oversaw a corporate rebranding, transitioning from SMS Lifesciences India Limited to Haleos Labs Limited in August 2025 to reflect its evolving market identity.
Growth Outlook
Growth is driven by the company's extensive portfolio of specialised API products and its established export operations. Continued focus on diverse therapeutic areas positions the firm to capture demand in both domestic and global pharmaceutical markets.
Key Risks
- Regulatory Compliance. The company faces stringent oversight from global health authorities, where any failure to meet manufacturing standards could lead to product recalls or export bans.
- Raw Material Price Volatility. Fluctuations in the cost of key starting materials and chemical intermediates can significantly impact operating margins.
- Foreign Exchange Risk. As an exporter, the company is exposed to currency volatility which may affect the competitiveness and profitability of its international sales.
- Competitive Pressure. The API manufacturing sector is highly fragmented, leading to intense price competition from other low-cost generic manufacturers.
Start your research today
Unlock AI insights, financials, peers and live data on Haleos Labs Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹324 Cr
TTM · consolidated
NET PROFIT
₹15 Cr
TTM · consolidated
EPS
₹52.27
TTM · consolidated
RETURN ON EQUITY
7.4%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
10.3%
TTM · consolidated
P/E
28.5x
Q1 FY27 · consolidated
EV/EBITDA
12.8x
Q1 FY27 · consolidated
EBITDA MARGIN
13.6%
TTM · consolidated
NET PROFIT MARGIN
2.5%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.5x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27